Open AccessProspects for successful treatment of Parkinson’s disease with the use of apomorphine
Author(s) -
I. N. Karaban,
Nina Karasevych,
Tetyana Hasiuk
Publication year - 2021
Publication title -
meždunarodnyj nevrologičeskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2307-1419
pISSN - 2224-0713
DOI - 10.22141/2224-0713.17.4.2021.237604
Subject(s) - apomorphine , medicine , tolerability , levodopa , dopaminergic , dopamine agonist , motor symptoms , disease , parkinson's disease , dopamine , quality of life (healthcare) , intensive care medicine , anesthesia , neuroscience , pharmacology , adverse effect , psychology , nursing
Optimizing the treatment of idiopathic Parkinson’s disease is a complex, multifaceted and continuous process that directly affects quality of life. The main position of this review is the need for individualized therapy that provides optimal motor function with the least negative consequences. Apomorphine, a dopamine agonist used as emergency therapy for patients with motor fluctuations with a potential positive effect on non-motor symptoms, is the only antiparkinsonian drug whose ability to control motor symptoms is equivalent to that of levodopa. Subcutaneous administration as a periodic injection is the most effective and affordable way to correct dopaminergic insufficiency in Parkinson’s disease. The data of multicenter studies presented in the review confirm the high efficiency, adequate tolerability and prospects of apomorphine use in comprehensive pathogenetic therapy of the disease. This review contains the historical reference and generalizes structure, the mechanism of action, pharmacodyna-mics, indications, contraindications and side effects in subcutaneous injections of apomorphine at the advanced stages of a clinical course of Parkinson’s disease.